Immunomedics Inc. (NASDAQ:IMMU) of Morris Plains, N.J.,announced that its monoclonal antibody-based colorectalcancer diagnostic imaging agent, ImmuRAID-CEA, was able toidentify occult cancers in 80 percent of patients in whomtumors were strongly suspected but were undetected byconventional diagnostic imaging. Yehuda Patt of the M.D.Anderson Cancer Center in Houston presented the clinical datafrom the 15-patient Phase III study at the AmericanAssociation for Cancer Research conference in Orlando, Fla.ImmuRAID-CEA is currently under review by the U.S. FDA andby regulatory agencies in Europe and Canada.

(c) 1997 American Health Consultants. All rights reserved.